Maia Biotechnology Inc (MAIA)

$MAIA Accumulation between .80s and 1.50 in my opinion. I don't think it will hit .80s again in the short terms.

$MAIA The same people complaining a month ago that they needed money without additional warrants are now upset despite having $30M to make it past the interim data readout without warrants, and they're still complaining. Translation: They're either shorts or just chronic complainers. Once, positive interim data is released, this chances everything within minutes. Either, get on the train now or move aside for others to board. NFA NYOR

$MAIA refi killed this

$MAIA Black clouds remain ahead. The Grim Reaper awaits. The seas are parting and filled with vermin. Landslides of hoodlums' fecal toxic discharges are being violently hurled at this failing stock. The bewitching hour is upon you all. Ominous signs are everywhere. The wagons are quickly circling this dead carcass. Time to throw in the towel. I have to use the restroom. Abandon ship at once. Hide the men, women, children, elderly and the mentally disabled. Take heed. No time to waste. It's curtains for this stock. Stick a fork in it. My ex-wife sold her body for crack. You all have been warned. Mayday, Mayday! The horizon spells gloom and doom. Get the coffin ready. Board up the building and doors. Call 911. Exit or perish. It's running on fumes. My dad likes oatmeal. This stock is toast. Somebody call the chaplain. Look out below! The pungent and rancid smell of death and decay is in the air. I own a recliner and loveseat. Please read my StockTwits Profile and next time heed my word.

$MAIA MAIA FAQ's 1. What is MAIA Biotechnology? ·MAIA is a clinical-stage biopharmaceutical company (founded 2018, headquartered in Chicago) developing first-in-class targeted immunotherapies. Its lead approach disrupts telomeres in telomerase-positive cancer cells (~85–90% of solid tumors), inducing cancer cell death and boosting immune responses—particularly for patients resistant to checkpoint inhibitors (CPI) and chemotherapy. 2. Where did the company name come from? MAIA is named after Maia Vitoc, the daughter of founder, Chairman, and CEO Dr. Vlad Vitoc, M.D., M.B.A. (This personal family inspiration is referenced in biotech investor communities, podcasts, and origin discussions.) 3. What is the lead product candidate? Ateganosine (THIO; 6-thio-2’-deoxyguanosine or 6-thio-dG) is a first-in-class small-molecule telomere-targeting agent. Incorporates into telomerase-active cancer cell DNA, causing telomeric instability and rapid cancer cell death. Stimulates immune activation. Administered sequentially before a CPI to convert "cold" tumors to "hot." Spares normal cells (low telomerase) and demonstrates strong synergy with immunotherapy—differentiating it from earlier telomerase inhibitors. 4. What is the current clinical status? Phase 2 (THIO-101) in advanced NSCLC: Strong ongoing data with median overall survival ~17.8 months in 3rd-line+ settings (vs. historical ~6 months with chemo); median PFS 5.6 months; notable long-term survivor at 30 months (912 days) as of late 2025. Part C expansion ongoing in Asia and Europe. Phase 3 pivotal trial (THIO-104) in 3rd-line NSCLC (resistant to prior immunotherapy/chemo): First patient dosed: December 11, 2025. Compares ateganosine sequenced with CPI (e.g., cemiplimab) vs. chemotherapy. FDA Fast Track designation (2025) supports potential accelerated/priority review. Primary endpoint: Overall survival (OS). 2026 milestones: Interim efficacy analyses (disease control rate/DCR, overall response rate/ORR, progression-free survival/PFS) expected; positive data could enable early regulatory discussions/approval pathway. Pipeline expansions: Planned trials in colorectal cancer, hepatocellular carcinoma, small-cell lung cancer, glioblastoma, and others. Second-generation telomere agents in preclinical/early development. Designations: Orphan Drug (e.g., SCLC, HCC, gliomas); Rare Pediatric Disease (high-grade gliomas). Market opportunity: Targets ~$50B global immunotherapy space, with NSCLC as key entry (~50,000 U.S. 3rd-line patients annually). 5. Why the excitement around pan-cancer potential? ·Ateganosine targets telomerase activation—a near-universal cancer hallmark—directly at telomeres. Mechanistic, preclinical, and early clinical data (e.g., NSCLC) suggest broad solid-tumor applicability, setting it apart from prior failed enzyme-focused telomerase inhibitors. 6. What about recent financing and stock risks? March 2026: Closed $30 million underwritten public offering on March 4 (20 million shares at $1.50/share; 30-day option for up to 3 million additional shares to cover over-allotments). Proceeds fund clinical trials (including Phase 3), operations, and working capital. Extends cash runway but involves typical dilution for clinical-stage biotechs. MAIA is a volatile micro-cap stock: Highly sensitive to clinical/regulatory news, trial enrollment, cash position, and market sentiment. Key upside catalysts: 2026 Phase 3 interim data, FDA Fast Track interactions, potential partnerships (e.g., existing CPI supply agreements with Roche and BeOne Medicines), and additional milestones. 7. Who leads the company? Founder, Chairman & CEO: Dr. Vlad Vitoc, M.D., M.B.A. — seasoned executive with over 25 years in pharma/biotech oncology development and leadership. Strong insider alignment: Insiders (officers/directors) hold ~9–13% collective ownership (e.g., Dr. Vitoc beneficially owns ~13% per recent filings; includes direct shares, options, and family trusts). Supported by scientific advisors specializing in telomere biology and immuno-oncology. 8. Where can I find official information? Company website: maiabiotech.com (pipeline, mechanism of action, background) Investor Relations: ir.maiabiotech.com (press releases, SEC filings, presentations, 2026 Shareholder Letter highlighting Phase 3 progress and market potential) Clinical trials: ClinicalTrials.gov (search THIO-101, THIO-104, ateganosine; NCT06908304 for THIO-104) Disclaimer: This is for educational/informational purposes only — NOT investment, medical, or financial advice. Clinical-stage biotechs carry very high risk of total capital loss. Results, timelines, and stock prices change rapidly. Always do your own research (DYOR), review official SEC filings/company disclosures, and consult professionals. More Information https://www.reddit.com/r/MAIABiotech/comments/1rwcsq4/maia_biotechnology_faq/

$MAIA GERN reached a $3B - $4B market cap after approval of their drug Rytelo, but due to their terrible commercial execution and small target market, they have drastically fallen. MAIA has the chance to reach $1B+ on approval, which would get us to about $11 per share fully diluted, or $17 if warrants aren't called in. The commercial potential for MAIA's drug THIO is orders of magnitude higher than Rytelo though, so if MAIA doesn't execute poorly like GERN, then $1B is an extremely conservative Market Cap. 🥂

$MAIA trash

$MAIA Going to be a pennystock

$MAIA Continuous shareholder dilution

$MAIA Why Early 2000's Telomerase-Directed Attempts Failed Early telomerase-directed therapies faced significant hurdles in the 2000s and 2010s. Classic approaches—like catalytic inhibitors (e.g., BIBR1532) or template antagonists (e.g., imetelstat/GRN163L)—primarily blocked telomerase's ability to add new repeats. This led to gradual telomere erosion over many cell divisions (often weeks to months in models), creating a long "phenotypic lag" before meaningful growth arrest or death occurred via replicative senescence or crisis. During this prolonged window, researchers worried about two main risks: Cancer cells could adapt by activating **alternative lengthening of telomeres (ALT)**, a recombination-based backup pathway (already used by 10–15% of cancers naturally). Surviving cells might acquire new mutations or genomic changes driven by progressive telomere dysfunction, potentially leading to more aggressive clones, therapy resistance, or even secondary malignancies in normal cells (though the latter concern was more theoretical for selective inhibitors). These lag-dependent limitations contributed to underwhelming clinical translation for many early candidates, despite promising preclinical data—efficacy often required very long exposure times, and resistance mechanisms were a realistic fear. THIO flips this paradigm with a fundamentally different mode of action. Instead of merely inhibiting telomerase enzyme activity, it serves as a **telomerase substrate** (a modified nucleotide analog). Telomerase actively recognizes and incorporates THIO into newly synthesized telomeric DNA during extension attempts. This poisons the telomere from the inside: The incorporated THIO disrupts proper t-loop formation and shelterin binding → immediate **telomere uncapping**. This triggers acute DNA damage signaling (ATM/ATR pathways, γ-H2AX foci, etc.) within hours to a few days. Cancer cells experience rapid mitotic catastrophe, apoptosis, or necrosis—often within just a few divisions (preclinical data show effects in 24–72 hours in many models). Because the damage hits so quickly and decisively, there's minimal opportunity for surviving cells to proliferate long enough to accumulate escape mutations, upregulate ALT, or develop classical resistance pathways. The cell is killed before it has "time to mutate" meaningfully in response to the insult. This rapid, direct lethality contrasts sharply with the slow attrition of traditional inhibitors. Supporting this, preclinical studies highlight THIO's ability to overcome resistance in models (e.g., TMZ-resistant gliomas, osimertinib-resistant NSCLC) without evidence of rapid emergence of new resistance mechanisms—likely due to the speed of kill. The additional immune activation (micronuclei → cGAS-STING → T-cell recruitment and memory) further reduces relapse risk by clearing residual cells immunologically. Summary In short, THIO's "incorporation → instant uncapping → fast death" strategy directly addresses the mutation/resistance concerns that plagued slower-acting 2000s-era telomerase strategies, making it a more promising candidate for broad, durable responses. https://www.reddit.com/r/MAIABiotech/comments/1ruq2xo/why_early_2000s_telomerasedirected_attempts_failed/